Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Joint and Lung Damage in Rheumatoid Arthritis

Case ID:
C14238
Disclosure Date:
11/9/2016
Description:
Unmet Need:  Rheumatoid Arthritis is a complex and clinically heterogeneous disease which presents a recognized challenge for diagnosis and prediction of future severity. Peptidylarginine deiminase (PAD) enzyme family members are known to be central players in the pathology of Rheumatoid Arthritis (RA). There is a need for precise biomarkers to identify clinically unique disease subgroups in order to help direct treatment plans.  In a subset of patients with RA, autoantibodies that activate some of these PAD enzymes have been identified. These antibodies are associated with severe joint and lung disease, highlighting the potential importance of functional autoantibodies in disease pathogenesis. JHU scientists have discovered that patients with auto-antibodies to another PAD family member have less severe joint damage and interstitial lung disease. Technical Details: JHU scientists found that clinical characteristics of anti-PAD positive patients were distinct from those previously observed for anti-PAD4 antibodies. Those patients with RA which had circulating anti-PAD antibodies had a reduced swollen joint count, had less interstitial lung disease and appear to be protected against radiographic progression. Anti-PAD antibodies represent a novel biomarker in RA that is not associated with the traditional risk factors linked to disease severity.  The antibodies represent a novel prognostic biomarker in RA that identifies a demographically unique subset of patients with less severe disease and suggests an unappreciated mechanistic role of one of the PADs in RA pathogenesis. This novel biomarker has potential implications for disease monitoring and highlights an unappreciated role of a PAD family member in RA pathogenesis. 
Stage of development/data: Pre-clinical. JHU is looking for partners to develop and clinically validate this assay.
Publications: Abstract Amer. Coll. Rheum November 2016 Meeting


 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
ANTI-PAD2 ANTIBODY FOR TREATING AND EVALUATING AUTOIMMUNE AND INFLAMMATORY DISEASES ORD: Ordinary Utility United States 15/945,411 4/4/2018     Pending
ANTI-PAD2 ANTIBODY FOR TREATING AND EVALUATING RHEUMATOID ARTHRITIS ORD: Ordinary Utility United States 15/945,396 4/4/2018     Pending
Inventors:
Category(s):
For Information, Contact:
Nakisha Holder
nickki@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum